You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRabeprazole
Accession NumberDB01129  (APRD01212)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionRabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
Structure
Thumb
Synonyms
Clofezone
Rabeprazole
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-rabeprazoleTablet, delayed release10 mgOralBgp Pharma Ulc2014-10-172015-12-31Canada
Abbott-rabeprazoleTablet, delayed release20 mgOralBgp Pharma Ulc2014-07-212015-12-31Canada
AciphexTablet, delayed release20 mg/1OralCarilion Materials Management1999-08-19Not applicableUs
AciphexTablet, coated20 mg/1OralCardinal Health1999-08-19Not applicableUs
AciphexTablet, coated20 mg/1Oralbryant ranch prepack1999-08-19Not applicableUs
AciphexTablet, coated20 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Produtcs LLC2012-02-17Not applicableUs
AciphexTablet, delayed release20 mg/1OralEisai Inc.1999-08-19Not applicableUs
AciphexTablet, delayed release20 mg/1OralPhysicians Total Care, Inc.2000-05-15Not applicableUs
Aciphex SprinkleCapsule, delayed release5 mg/1OralFsc Laboratories, Inc.2014-10-01Not applicableUs
Aciphex SprinkleCapsule, delayed release10 mg/1OralFsc Laboratories, Inc.2014-10-01Not applicableUs
Dom-rabeprazole ECTablet, delayed release10 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-rabeprazole ECTablet, delayed release20 mgOralDominion Pharmacal2012-09-26Not applicableCanada
Mylan-rabeprazoleTablet, delayed release20 mgOralMylan Pharmaceuticals Ulc2013-07-10Not applicableCanada
Mylan-rabeprazoleTablet, delayed release10 mgOralMylan Pharmaceuticals Ulc2013-07-10Not applicableCanada
Ntp-rabeprazole ECTablet, delayed release10 mgOralNt Pharma Canada LtdNot applicableNot applicableCanada
Ntp-rabeprazole ECTablet, delayed release20 mgOralNt Pharma Canada LtdNot applicableNot applicableCanada
Pariet, Enteric-coated Tablet 10mgTablet, delayed release10 mgOralJanssen Inc2002-04-02Not applicableCanada
Pariet, Enteric-coated Tablet 20mgTablet, delayed release20 mgOralJanssen Inc2002-04-02Not applicableCanada
Pat-rabeprazoleTablet, delayed release20 mgOralPatriot A Division Of Janssen Inc2012-05-082014-11-18Canada
Pat-rabeprazoleTablet, delayed release10 mgOralPatriot A Division Of Janssen Inc2012-05-082014-11-11Canada
PMS-rabeprazole ECTablet, delayed release10 mgOralPharmascience Inc2008-06-03Not applicableCanada
PMS-rabeprazole ECTablet, delayed release20 mgOralPharmascience Inc2008-06-03Not applicableCanada
Pro-rabeprazoleTablet, delayed release10 mgOralPro Doc Limitee2009-02-10Not applicableCanada
Pro-rabeprazoleTablet, delayed release20 mgOralPro Doc Limitee2009-02-10Not applicableCanada
RabeprazoleTablet, delayed release10 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
RabeprazoleTablet, delayed release20 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Rabeprazole ECTablet, delayed release20 mgOralSanis Health Inc2010-11-23Not applicableCanada
Rabeprazole ECTablet, delayed release10 mgOralMeliapharm Inc2010-02-182014-06-25Canada
Rabeprazole ECTablet, delayed release20 mgOralMeliapharm Inc2010-02-182014-06-25Canada
Rabeprazole ECTablet, delayed release10 mgOralSanis Health Inc2010-11-23Not applicableCanada
Ran-rabeprazoleTablet, delayed release20 mgOralRanbaxy Pharmaceuticals Canada Inc.2007-11-09Not applicableCanada
Ran-rabeprazoleTablet, delayed release10 mgOralRanbaxy Pharmaceuticals Canada Inc.2007-11-09Not applicableCanada
Ran-rabeprazole ECTablet, delayed release20 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-rabeprazole ECTablet, delayed release10 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Riva-rabeprazole ECTablet, delayed release10 mgOralLaboratoire Riva Inc2009-09-28Not applicableCanada
Riva-rabeprazole ECTablet, delayed release20 mgOralLaboratoire Riva Inc2009-09-30Not applicableCanada
Sandoz RabeprazoleTablet, delayed release20 mgOralSandoz Canada Incorporated2008-07-29Not applicableCanada
Sandoz RabeprazoleTablet, delayed release10 mgOralSandoz Canada Incorporated2008-07-29Not applicableCanada
Teva-rabeprazole ECTablet, delayed release10 mgOralTeva Canada Limited2007-11-13Not applicableCanada
Teva-rabeprazole ECTablet, delayed release20 mgOralTeva Canada Limited2007-11-13Not applicableCanada
Torrent-rabeprazole SodiumTablet, delayed release10 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-rabeprazole SodiumTablet, delayed release20 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-rabeprazoleTablet, delayed release10 mgOralApotex Inc2012-05-01Not applicableCanada
Apo-rabeprazoleTablet, delayed release20 mgOralApotex Inc2012-05-01Not applicableCanada
Rabeprazole SodiumTablet, delayed release20 mg/1OralREMEDYREPACK INC.2016-08-11Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralProficient Rx LP2013-11-08Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralKremers Urban Pharmaceuticals Inc.2013-11-08Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralMajor Pharmaceuticals2013-11-08Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralUnit Dose Services2013-11-08Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralA S Medication Solutions2013-11-08Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralTeva Pharmaceuticals Usa, Inc.2013-11-08Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralProficient Rx LP2013-11-08Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralMylan Pharmaceuticals Inc.2013-11-08Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralTorrent Pharmaceuticals Limited2013-11-08Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralGolden State Medical Supply, Inc.2015-03-02Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralUnit Dose Services2015-10-01Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralA S Medication Solutions2013-11-08Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralAmneal Pharmaceuticals of New York, LLC2015-10-01Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralLupin Pharmaceuticals, Inc.2013-11-08Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralAv Kare, Inc.2013-12-23Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralProficient Rx LP2013-11-082016-10-13Us
Rabeprazole SodiumTablet, delayed release20 mg/1OralProficient Rx LP2013-11-08Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralBreckenridge Pharmaceutical, Inc.2016-08-01Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralPreferred Pharmaceuticals Inc.2015-08-27Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralPreferred Pharmaceuticals Inc.2015-05-13Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralAv Kare, Inc.2013-12-19Not applicableUs
Rabeprazole SodiumTablet, delayed release20 mg/1OralPreferred Pharmaceuticals Inc.2016-02-11Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ParietNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Rabeprazole Sodium
117976-90-6
Thumb
  • InChI Key: KRCQSTCYZUOBHN-UHFFFAOYNA-N
  • Monoisotopic Mass: 381.112306886
  • Average Mass: 381.424
DBSALT000552
Categories
UNII32828355LL
CAS number117976-89-3
WeightAverage: 359.443
Monoisotopic: 359.130362243
Chemical FormulaC18H21N3O3S
InChI KeyYREYEVIYCVEVJK-UHFFFAOYSA-N
InChI
InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)
IUPAC Name
2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole
SMILES
COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1
Pharmacology
IndicationFor the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
Structured Indications
PharmacodynamicsRabeprazole prevents the production of acid in the stomach. It reduces symptoms and prevents injury to the esophagus or stomach in patients with gastroesophageal reflux disease (GERD) or ulcers. Rabeprazole is also useful in conditions that produce too much stomach acid such as Zollinger-Ellison syndrome. Rabeprazole may also be used with antibiotics to get rid of bacteria that are associated with some ulcers. Rabeprazole is a selective and irreversible proton pump inhibitor, suppresses gastric acid secretion by specific inhibition of the H+, K+ -ATPase, which is found at the secretory surface of parietal cells. In doing so, it inhibits the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen.
Mechanism of actionRabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds.
TargetKindPharmacological actionActionsOrganismUniProt ID
Potassium-transporting ATPase alpha chain 1Proteinyes
inhibitor
HumanP20648 details
Related Articles
AbsorptionAbsolute bioavailability is approximately 52%.
Volume of distributionNot Available
Protein binding96.3% (bound to human plasma proteins)
Metabolism

Hepatic

SubstrateEnzymesProduct
Rabeprazole
Not Available
Active Metabolite of RabeprazoleDetails
Route of eliminationFollowing a single 20 mg oral dose of 14C-labeled rabeprazole, approximately 90% of the drug was eliminated in the urine, primarily as thioether carboxylic acid; its glucuronide, and mercapturic acid metabolites.
Half life1-2 hours (in plasma)
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Rabeprazole Metabolism PathwayDrug metabolismSMP00616
Rabeprazole Action PathwayDrug actionSMP00229
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe metabolism of Rabeprazole can be decreased when combined with Abiraterone.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Rabeprazole.Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Rabeprazole.Approved, Vet Approved
Alendronic acidThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Rabeprazole.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Rabeprazole.Approved, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Rabeprazole.Approved, Withdrawn
AmiodaroneThe metabolism of Rabeprazole can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Rabeprazole.Approved
AmodiaquineThe metabolism of Amodiaquine can be decreased when combined with Rabeprazole.Approved
AmphetamineRabeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Rabeprazole.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Rabeprazole.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Rabeprazole.Approved
AprepitantThe serum concentration of Rabeprazole can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Rabeprazole.Approved, Investigational
ArmodafinilThe metabolism of Rabeprazole can be decreased when combined with Armodafinil.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Rabeprazole.Approved, Investigational
AtomoxetineThe metabolism of Rabeprazole can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Rabeprazole.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Rabeprazole.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Rabeprazole.Approved
BeraprostThe metabolism of Beraprost can be decreased when combined with Rabeprazole.Investigational
BexaroteneThe serum concentration of Rabeprazole can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Rabeprazole can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Rabeprazole can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Rabeprazole can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Rabeprazole.Approved
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Rabeprazole.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Rabeprazole.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Rabeprazole.Approved
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Rabeprazole.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Rabeprazole.Approved
CarbamazepineThe metabolism of Rabeprazole can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Rabeprazole.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Rabeprazole.Approved
CeritinibThe serum concentration of Rabeprazole can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Rabeprazole.Withdrawn
ChloramphenicolThe metabolism of Rabeprazole can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Rabeprazole.Approved, Vet Approved
CholecalciferolThe metabolism of Rabeprazole can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Rabeprazole.Approved
CimetidineThe metabolism of Rabeprazole can be decreased when combined with Cimetidine.Approved
CisaprideThe metabolism of Cisapride can be decreased when combined with Rabeprazole.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Rabeprazole can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Rabeprazole can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Rabeprazole can be decreased when combined with Clemastine.Approved
ClodronateThe therapeutic efficacy of Clodronate can be decreased when used in combination with Rabeprazole.Approved, Investigational, Vet Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Rabeprazole resulting in a loss in efficacy.Approved, Nutraceutical
ClotrimazoleThe metabolism of Rabeprazole can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Rabeprazole.Approved
CobicistatThe metabolism of Rabeprazole can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Rabeprazole can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Rabeprazole can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Rabeprazole.Approved, Investigational
CyclosporineThe metabolism of Rabeprazole can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Rabeprazole.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Rabeprazole resulting in a loss in efficacy.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Rabeprazole.Approved
DapsoneThe metabolism of Dapsone can be decreased when combined with Rabeprazole.Approved, Investigational
DarunavirThe metabolism of Rabeprazole can be decreased when combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Rabeprazole.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Rabeprazole.Approved, Investigational
DeferasiroxThe serum concentration of Rabeprazole can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Rabeprazole.Approved
DexamethasoneThe serum concentration of Rabeprazole can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmethylphenidateRabeprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineRabeprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Rabeprazole.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Rabeprazole.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Rabeprazole.Approved, Vet Approved
DihydroergotamineThe metabolism of Rabeprazole can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Rabeprazole can be decreased when combined with Diltiazem.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Rabeprazole.Approved, Investigational, Vet Approved
DoxycyclineThe metabolism of Rabeprazole can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Rabeprazole can be decreased when combined with Dronedarone.Approved
EfavirenzThe serum concentration of Rabeprazole can be decreased when it is combined with Efavirenz.Approved, Investigational
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Rabeprazole.Approved
EnzalutamideThe serum concentration of Rabeprazole can be decreased when it is combined with Enzalutamide.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Rabeprazole.Approved, Investigational
ErythromycinThe metabolism of Rabeprazole can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Rabeprazole can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Rabeprazole can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe metabolism of Estradiol can be decreased when combined with Rabeprazole.Approved, Investigational, Vet Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Rabeprazole.Approved
Etidronic acidThe therapeutic efficacy of Etidronic acid can be decreased when used in combination with Rabeprazole.Approved
EtravirineThe serum concentration of Rabeprazole can be decreased when it is combined with Etravirine.Approved
Ferric CarboxymaltoseRabeprazole can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateRabeprazole can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateRabeprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rabeprazole.Approved
FluconazoleThe serum concentration of Rabeprazole can be increased when it is combined with Fluconazole.Approved
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Rabeprazole.Approved
FluoxetineThe metabolism of Rabeprazole can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Rabeprazole.Approved
FluvoxamineThe metabolism of Rabeprazole can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Rabeprazole can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Rabeprazole can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Rabeprazole can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Rabeprazole can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Rabeprazole.Approved, Investigational
GemfibrozilThe metabolism of Rabeprazole can be decreased when combined with Gemfibrozil.Approved
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Rabeprazole.Approved
IbandronateThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Rabeprazole.Approved, Investigational
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Rabeprazole.Approved
IdelalisibThe serum concentration of Rabeprazole can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Rabeprazole.Approved
ImatinibThe metabolism of Rabeprazole can be decreased when combined with Imatinib.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Rabeprazole.Approved
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Rabeprazole.Approved, Investigational
IronRabeprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranRabeprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateRabeprazole can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsavuconazoniumThe metabolism of Rabeprazole can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Rabeprazole can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Rabeprazole can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Rabeprazole.Approved, Investigational
IvacaftorThe serum concentration of Rabeprazole can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Rabeprazole.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Rabeprazole.Approved, Vet Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Rabeprazole.Approved
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Rabeprazole.Approved, Investigational
KetoconazoleThe metabolism of Rabeprazole can be decreased when combined with Ketoconazole.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Rabeprazole.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Rabeprazole.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Rabeprazole.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Rabeprazole.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Rabeprazole.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Rabeprazole.Approved, Vet Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Rabeprazole.Approved
LopinavirThe metabolism of Rabeprazole can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Rabeprazole.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Rabeprazole.Approved
LovastatinThe metabolism of Rabeprazole can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Rabeprazole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Rabeprazole can be decreased when it is combined with Lumacaftor.Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Rabeprazole.Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Rabeprazole.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Rabeprazole.Investigational, Withdrawn
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Rabeprazole.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Rabeprazole.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Rabeprazole.Approved
MethylphenidateRabeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Rabeprazole.Approved, Investigational
MifepristoneThe serum concentration of Rabeprazole can be increased when it is combined with Mifepristone.Approved, Investigational
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Rabeprazole.Approved
MitotaneThe serum concentration of Rabeprazole can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Rabeprazole can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Rabeprazole can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe metabolism of Morphine can be decreased when combined with Rabeprazole.Approved, Investigational
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Rabeprazole.Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Rabeprazole.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rabeprazole.Approved
NafcillinThe serum concentration of Rabeprazole can be decreased when it is combined with Nafcillin.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Rabeprazole.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Rabeprazole.Approved, Vet Approved
NefazodoneThe metabolism of Rabeprazole can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Rabeprazole resulting in a loss in efficacy.Approved
NetupitantThe serum concentration of Rabeprazole can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Rabeprazole can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Rabeprazole can be decreased when combined with Nicardipine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Rabeprazole.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Rabeprazole.Approved, Investigational
OlaparibThe metabolism of Rabeprazole can be decreased when combined with Olaparib.Approved
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Rabeprazole.Approved
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Rabeprazole.Approved
OmeprazoleThe metabolism of Rabeprazole can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Rabeprazole can be increased when it is combined with Osimertinib.Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Rabeprazole.Approved, Vet Approved
PalbociclibThe serum concentration of Rabeprazole can be increased when it is combined with Palbociclib.Approved
PamidronateThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Rabeprazole.Approved
PantoprazoleThe metabolism of Rabeprazole can be decreased when combined with Pantoprazole.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Rabeprazole.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Rabeprazole.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Rabeprazole.Approved
PentobarbitalThe metabolism of Rabeprazole can be increased when combined with Pentobarbital.Approved, Vet Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Rabeprazole.Approved
PhenobarbitalThe metabolism of Rabeprazole can be increased when combined with Phenobarbital.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Rabeprazole.Approved
PhenytoinThe metabolism of Rabeprazole can be increased when combined with Phenytoin.Approved, Vet Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Rabeprazole.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Rabeprazole.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Rabeprazole.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Rabeprazole.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Rabeprazole.Approved, Investigational, Vet Approved
PrimidoneThe metabolism of Rabeprazole can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Rabeprazole.Approved, Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Rabeprazole.Approved, Investigational, Vet Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Rabeprazole.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Rabeprazole.Approved
RaltegravirThe serum concentration of Raltegravir can be increased when it is combined with Rabeprazole.Approved
RanolazineThe metabolism of Rabeprazole can be decreased when combined with Ranolazine.Approved, Investigational
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Rabeprazole.Approved, Investigational
RifabutinThe metabolism of Rabeprazole can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Rabeprazole can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Rabeprazole can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Rabeprazole.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Rabeprazole.Approved
RisedronateThe therapeutic efficacy of Risedronate can be decreased when used in combination with Rabeprazole.Approved, Investigational
RitonavirThe metabolism of Rabeprazole can be decreased when combined with Ritonavir.Approved, Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Rabeprazole.Investigational, Withdrawn
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Rabeprazole.Approved, Investigational
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Rabeprazole.Approved, Investigational
SelegilineThe metabolism of Selegiline can be decreased when combined with Rabeprazole.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Rabeprazole.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Rabeprazole.Approved, Investigational
SertralineThe metabolism of Rabeprazole can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Rabeprazole can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Rabeprazole can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Rabeprazole can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Rabeprazole.Approved
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Rabeprazole.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Rabeprazole.Approved, Investigational
St. John's WortThe serum concentration of Rabeprazole can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Rabeprazole can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Rabeprazole.Approved, Vet Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Rabeprazole.Approved
SulfisoxazoleThe metabolism of Rabeprazole can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Rabeprazole.Approved, Investigational
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Rabeprazole.Approved, Investigational
Technetium tc 99m etidronateThe therapeutic efficacy of Technetium tc 99m etidronate can be decreased when used in combination with Rabeprazole.Approved
Technetium Tc-99m MedronateThe therapeutic efficacy of Technetium Tc-99m Medronate can be decreased when used in combination with Rabeprazole.Approved
TelaprevirThe metabolism of Rabeprazole can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Rabeprazole can be decreased when combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Rabeprazole.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Rabeprazole.Approved, Investigational, Vet Approved
TestosteroneThe metabolism of Testosterone can be decreased when combined with Rabeprazole.Approved, Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Rabeprazole.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Rabeprazole.Approved
TiclopidineThe metabolism of Rabeprazole can be decreased when combined with Ticlopidine.Approved
TiludronateThe therapeutic efficacy of Tiludronate can be decreased when used in combination with Rabeprazole.Approved, Vet Approved
TipranavirThe serum concentration of Rabeprazole can be decreased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Rabeprazole can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Rabeprazole.Approved
TopiramateThe metabolism of Rabeprazole can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Rabeprazole.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Rabeprazole.Approved
TranylcypromineThe metabolism of Rabeprazole can be decreased when combined with Tranylcypromine.Approved
TretinoinThe metabolism of Tretinoin can be decreased when combined with Rabeprazole.Approved, Investigational, Nutraceutical
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Rabeprazole.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Rabeprazole.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Rabeprazole.Withdrawn
VenlafaxineThe metabolism of Rabeprazole can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Rabeprazole can be decreased when combined with Verapamil.Approved
VoriconazoleThe serum concentration of Rabeprazole can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Rabeprazole.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Rabeprazole.Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Rabeprazole.Approved, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Rabeprazole.Approved
ZiprasidoneThe metabolism of Rabeprazole can be decreased when combined with Ziprasidone.Approved
Zoledronic acidThe therapeutic efficacy of Zoledronic acid can be decreased when used in combination with Rabeprazole.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Rabeprazole.Approved
Food Interactions
  • Take without regard to meals.
  • Take without regard to meals. Food may slow absorption rate but extent of absorption is not affected.
References
Synthesis Reference

Sundaram Venkatraman, “Crystalline form Z of rabeprazole sodium and process for preparation thereof.” U.S. Patent US20040180935, issued September 16, 2004.

US20040180935
General ReferencesNot Available
External Links
ATC CodesA02BC04M01AA05M02AA03A02BC54
AHFS Codes
  • 56:28.36
PDB EntriesNot Available
FDA labelDownload (135 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9967
Blood Brain Barrier+0.6469
Caco-2 permeable+0.6664
P-glycoprotein substrateSubstrate0.6179
P-glycoprotein inhibitor IInhibitor0.5835
P-glycoprotein inhibitor IINon-inhibitor0.9387
Renal organic cation transporterInhibitor0.6194
CYP450 2C9 substrateNon-substrate0.8265
CYP450 2D6 substrateNon-substrate0.8623
CYP450 3A4 substrateSubstrate0.7174
CYP450 1A2 substrateInhibitor0.6677
CYP450 2C9 inhibitorNon-inhibitor0.7734
CYP450 2D6 inhibitorNon-inhibitor0.7875
CYP450 2C19 inhibitorInhibitor0.6661
CYP450 3A4 inhibitorNon-inhibitor0.6647
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7243
Ames testNon AMES toxic0.5726
CarcinogenicityNon-carcinogens0.8751
BiodegradationNot ready biodegradable0.939
Rat acute toxicity2.4215 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5726
hERG inhibition (predictor II)Non-inhibitor0.8733
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tablet, coatedOral20 mg/1
Capsule, delayed releaseOral10 mg/1
Capsule, delayed releaseOral5 mg/1
Tablet, delayed releaseOral10 mg
Tablet, delayed releaseOral20 mg
Tablet, delayed releaseOral20 mg/1
Prices
Unit descriptionCostUnit
Aciphex 20 mg Enteric Coated Tabs7.48USD tab
Aciphex ec 20 mg tablet6.08USD tablet
Aciphex 20 mg tablet ec5.9USD tablet
Pariet 20 mg Enteric-Coated Tablet1.46USD tablet
Apo-Rabeprazole 20 mg Enteric-Coated Tablet0.82USD tablet
Novo-Rabeprazole 20 mg Enteric-Coated Tablet0.82USD tablet
Pms-Rabeprazole Ec 20 mg Enteric-Coated Tablet0.82USD tablet
Ran-Rabeprazole 20 mg Enteric-Coated Tablet0.82USD tablet
Sandoz Rabeprazole 20 mg Enteric-Coated Tablet0.82USD tablet
Pariet 10 mg Enteric-Coated Tablet0.73USD tablet
Apo-Rabeprazole 10 mg Enteric-Coated Tablet0.41USD tablet
Novo-Rabeprazole 10 mg Enteric-Coated Tablet0.41USD tablet
Pms-Rabeprazole Ec 10 mg Enteric-Coated Tablet0.41USD tablet
Ran-Rabeprazole 10 mg Enteric-Coated Tablet0.41USD tablet
Sandoz Rabeprazole 10 mg Enteric-Coated Tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1336958 No1995-09-122012-09-12Canada
CA2104531 No1999-01-052013-08-20Canada
US5045552 No1993-05-082013-05-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP0.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.336 mg/mLALOGPS
logP2.04ALOGPS
logP2.09ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)9.35ChemAxon
pKa (Strongest Basic)4.24ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area77.1 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity98.07 m3·mol-1ChemAxon
Polarizability39.64 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzimidazoles
Sub ClassSulfinylbenzimidazoles
Direct ParentSulfinylbenzimidazoles
Alternative Parents
Substituents
  • Sulfinylbenzimidazole
  • Methylpyridine
  • Alkyl aryl ether
  • Benzenoid
  • Pyridine
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Sulfoxide
  • Azacycle
  • Sulfinyl compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium-exchanging atpase activity
Specific Function:
Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.
Gene Name:
ATP4A
Uniprot ID:
P20648
Molecular Weight:
114117.74 Da
References
  1. Langtry HD, Markham A: Rabeprazole: a review of its use in acid-related gastrointestinal disorders. Drugs. 1999 Oct;58(4):725-42. [PubMed:10551440 ]
  2. Carswell CI, Goa KL: Rabeprazole: an update of its use in acid-related disorders. Drugs. 2001;61(15):2327-56. [PubMed:11772142 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Shimizu M, Uno T, Yasui-Furukori N, Sugawara K, Tateishi T: Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603. Epub 2006 Jun 17. [PubMed:16783561 ]
  3. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [PubMed:15258107 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Shimizu M, Uno T, Yasui-Furukori N, Sugawara K, Tateishi T: Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603. Epub 2006 Jun 17. [PubMed:16783561 ]
  3. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [PubMed:15258107 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [PubMed:15258107 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [PubMed:15258107 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. doi: 10.1111/j.1365-2125.2008.03303.x. Epub 2008 Nov 17. [PubMed:19076159 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23